FDA reviewers cast doubt on Insys analgesic's utility, safety

FDA reviewers said data from an NDA of Buvaya buprenorphine sublingual spray from Insys Therapeutics Inc. (NASDAQ:INSY) do not support

Read the full 209 word article

User Sign In